Invention Grant
- Patent Title: Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
-
Application No.: US14644801Application Date: 2015-03-11
-
Publication No.: US09675588B2Publication Date: 2017-06-13
- Inventor: Reza Fathi , Gilead Raday , Guy Goldberg
- Applicant: RedHill Biopharma Ltd.
- Applicant Address: IL Tel-Aviv
- Assignee: RedHill Biopharma Ltd.
- Current Assignee: RedHill Biopharma Ltd.
- Current Assignee Address: IL Tel-Aviv
- Agency: Greenberg Traurig, LLP
- Main IPC: A61K9/24
- IPC: A61K9/24 ; A61K31/4178 ; A61P1/08 ; A61P1/12 ; A61K9/20 ; A61K9/28

Abstract:
A method of treating a patient comprises orally administering a solid oral dosage form comprising a core comprising a non-ionic polymer matrix, a first amount of ondansetron dispersed within the matrix, and a salt dispersed within the matrix, wherein the first amount of ondansetron ranges from about 9 mg to about 28 mg; a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix; and an immediate release drug layer surrounding the first seal coat and comprising a non-ionic polymer and a second amount of ondansetron dispersed therein, wherein the second amount of ondansetron ranges from about 3 mg to about 8 mg, wherein release of ondansetron from the solid oral dosage form provides exposure to ondansetron for a minimum period of 16 hours so as to result in a reduction in frequency of vomiting, nausea, diarrhea, or a combination thereof.
Public/Granted literature
Information query